A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
Phase of Trial: Phase III
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics; Antineoplastics
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms KEYNOTE-587
- Sponsors Merck Sharp & Dohme
- 20 Aug 2018 Status changed from not yet recruiting to recruiting.
- 04 Jul 2018 Planned initiation date changed from 7 May 2018 to 17 Aug 2018.
- 06 Apr 2018 New trial record